More neo-volumab.

Oral cavity cancer is bad. Not least of which is due to the significant morbidity incurred by definitive treatments. This phase 2 trial (abstract 1) administered a short course of neoadjuvant nivolumab +/- ipilimumab followed by resection 3-7 days later for 30 patients with T2+ and/or N1+ squamous cell carcinoma (SCC) of the oral cavity. While -itis toxicities were as expected, importantly no surgery was delayed due to neoadjuvant treatment. At the time of resection, over two-thirds achieved a volumetric response, over one-third achieved a >50% pathologic response and remarkably 4 (13%) achieved a complete path response. TBL: Short-course neoadjuvant immune checkpoint inhibitors may pave the way for much needed deintensification of definitive therapy for oral cavity SCC. | Schoenfeld, Multi-D H&N Cancers Symposium 2020